Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer R Ribeiro

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|February 26, 2014
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancerJennifer R Ribeiro, Richard N Freiman
Oncogene|January 15, 2022
Prognostic immunologic signatures in epithelial ovarian cancerNicole E James, Morgan Woodman, Jennifer R Ribeiro
Frontiers in Oncology|May 10, 2018
Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian CancerNicole E James, Clinton Chichester, Jennifer R Ribeiro
Cancers|August 7, 2020
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian CancerNicole E James, Morgan Woodman, Paul A DiSilvestro, et al.
Frontiers in Oncology|March 22, 2014
Targeting TBP-Associated Factors in Ovarian CancerJennifer R Ribeiro, Lindsay A Lovasco, Barbara C Vanderhyden, et al.
Medical Oncology (Northwood, London, England)|May 14, 2022
A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expressionNicole E James, Megan Gura, Morgan Woodman, et al.
Frontiers in Oncology|March 22, 2021
Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian CancerNicole E James, Katherine Miller, Natalie LaFranzo, et al.
Scientific Reports|October 16, 2015
Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cellsKyu Kwang Kim, Sarah Abelman, Naohiro Yano, et al.
Scientific Reports|November 17, 2015
Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancersKyu Kwang Kim, Alex Han, Naohiro Yano, et al.
Oncology Letters|May 9, 2022
Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancerNicole E James, Ashley D Valenzuela, Jenna B Emerson, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
The Journal of Steroid Biochemistry and Molecular Biology|February 26, 2014
Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancerJennifer R Ribeiro, Richard N Freiman
Oncogene|January 15, 2022
Prognostic immunologic signatures in epithelial ovarian cancerNicole E James, Morgan Woodman, Jennifer R Ribeiro
Frontiers in Oncology|May 10, 2018
Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian CancerNicole E James, Clinton Chichester, Jennifer R Ribeiro
Cancers|August 7, 2020
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian CancerNicole E James, Morgan Woodman, Paul A DiSilvestro, et al.
Frontiers in Oncology|March 22, 2014
Targeting TBP-Associated Factors in Ovarian CancerJennifer R Ribeiro, Lindsay A Lovasco, Barbara C Vanderhyden, et al.
Medical Oncology (Northwood, London, England)|May 14, 2022
A bioinformatic analysis of WFDC2 (HE4) expression in high grade serous ovarian cancer reveals tumor-specific changes in metabolic and extracellular matrix gene expressionNicole E James, Megan Gura, Morgan Woodman, et al.
Frontiers in Oncology|March 22, 2021
Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian CancerNicole E James, Katherine Miller, Natalie LaFranzo, et al.
Scientific Reports|October 16, 2015
Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cellsKyu Kwang Kim, Sarah Abelman, Naohiro Yano, et al.
Scientific Reports|November 17, 2015
Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancersKyu Kwang Kim, Alex Han, Naohiro Yano, et al.
Oncology Letters|May 9, 2022
Intratumoral expression analysis reveals that OX40 and TIM-3 are prominently expressed and have variable associations with clinical outcomes in high grade serous ovarian cancerNicole E James, Ashley D Valenzuela, Jenna B Emerson, et al.
Pageof 4